iPS Cells & Regenerative Medicine– category –
-
Century Therapeutics Targets Q4 2026 IND Submission for iPSC-Derived CNTY-813 in Type 1 Diabetes, Advances CAR-iT Cell Therapy CNTY-308 Towards Clinical Trials This Year
Century Therapeutics, Inc. (Press Release) USA Overview Century Therapeutics announced that it has completed its pre-IND meeting with the FDA for CNTY-813, an iPSC-derived cell therapy for Type 1 diabetes, targeting an Investigational Ne... -
Allogene Therapeutics’ Off-the-Shelf CAR-T Cema-cel Achieves 58.3% MRD Negativity in ALPHA3 Phase 2 LBCL Trial, Securing FDA RMAT and Fast Track Designations
Allogene Therapeutics, Inc. (Press Release) USA Overview Allogene Therapeutics announced strong Q2 2026 results, highlighting that its off-the-shelf CAR T-cell therapy, cema-cel, achieved a robust 58.3% minimal residual disease (MRD) neg... -
Autolus Therapeutics Reports 119% YoY Increase in Q2 2026 AUCATZYL® Net Product Sales to $45.7M, Raising Full-Year Guidance and Securing $250M Credit Facility for Extended Runway
Autolus Therapeutics, Inc. (Press Release via GlobeNewswire) USA Overview Autolus Therapeutics announced that its CAR T-cell therapy, AUCATZYL® (obecabtagene autoleucel; obe-cel), generated $45.7 million in net product sales for Q2 2026,... -
Reprogramming the Future: Liv Hospital Details iPSC Therapy’s Transformative Role in Regenerative Medicine
Liv Hospital Turkey Overview Liv Hospital recently published an insightful article on induced pluripotent stem cell (iPSC) therapy, highlighting its profound impact on regenerative medicine, diverse applications, and global clinical prog... -
CRISPR’s Clinical Horizon: Liv Hospital Report Maps 2026 FDA Landscape and Broad Therapeutic Potential
Liv Hospital Turkey Overview Liv Hospital has published a comprehensive review outlining the latest advancements in CRISPR gene-editing technology, emphasizing its revolutionary impact on medical treatments. The report highlights breakth... -
NIH-Funded Team Discovers Miniaturized Al3Cas12f CRISPR Enzyme, Dramatically Enhancing In Vivo Precision Delivery and Solving a Major Gene Therapy Bottleneck
National Institutes of Health (NIH) (News Release) USA Overview An NIH-funded research team has discovered an improved CRISPR gene-editing system enabling precise in vivo gene delivery. This breakthrough involves identifying the naturall... -
USC Viterbi Engineers Develop ‘SHIFTERS’ Strategy to Enhance CAR T-Cell Efficacy Against Solid Tumors Using Hypoxia and Focused Ultrasound for Inducible CD19 Expression
Bioengineer.org USA Overview Researchers at the USC Viterbi School of Engineering have developed 'SHIFTERS,' a novel strategy to boost CAR T-cell efficacy against solid tumors. This innovative approach leverages tumor hypoxia and focused... -
MD Anderson Researchers Identify Immature NK Cell Subpopulation in Donor Umbilical Cord Blood That Compromises CAR-NK Cell Therapy Antitumor Activity
Mirage News USA Overview Researchers at MD Anderson have discovered that a specific subpopulation of immature natural killer (NK) cells found in donor umbilical cord blood can diminish the antitumor activity of chimeric antigen receptor ... -
Sana Biotechnology Advances Hypoimmune iPSC-Derived SC451 for Type 1 Diabetes and In Vivo CAR T SG293 for Non-Hodgkin Lymphoma Towards Clinical Entry, Bolstered by NEJM Publication of Long-Term Pancreatic Islet Data
Sana Biotechnology, Inc. (Press Release) USA Overview Sana Biotechnology reported significant progress towards initiating clinical trials for SC451, an iPSC-derived pancreatic islet cell therapy for Type 1 diabetes, and SG293, an in vivo... -
Fate Therapeutics Initiates Phase 2 Trial for iPSC-Derived Off-the-Shelf CAR T-Cell Therapy FT819 in Lupus Nephritis, Gains FDA IND Approval for Autoimmune FT839
Fate Therapeutics, Inc. (Press Release) USA Overview Fate Therapeutics reported significant advancements in its iPSC-derived off-the-shelf CAR T-cell immunotherapy pipeline, with the first patient dosed in the Phase 2 RECLAIM-LN study of...
